Physician profile
Deepika Aneja
NPI 1083888135
$178,129.63
in general payments reported to CMS, 2019-2025
31 companies · $4,855 in 2025
The $4,855 reported for 2025 was more than what 88% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $470 · 2020: $13K · 2021: $29K · 2022: $58K · 2023: $63K · 2024: $9,541 · 2025: $4,855.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $67K · Food and Beverage: $7,923 · Consulting Fee: $1,581 · Travel and Lodging: $358 · Education: $223.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $67,275.00 |
| Food and Beverage | $7,923.23 |
| Consulting Fee | $1,581.00 |
| Travel and Lodging | $357.87 |
| Education | $222.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $167,525.88 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Genzyme Corporation | $1,816.08 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,666.52 | 2019-2025 | Breztri, Airsupra, Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $984.42 | 2019-2025 | Ofev, Jascayd, Stiolto Respimat |
| Harmony Biosciences LLC | $562.79 | 2020-2025 | Wakix |
| Grifols USA, LLC | $557.29 | 2019-2025 | Prolastin-C Liquid |
| Takeda Pharmaceuticals U.S.A., INC. | $515.10 | 2022-2025 | Glassia |
| Regeneron Healthcare Solutions, INC. | $508.94 | 2019-2025 | Dupixent |
| Insmed, INC. | $412.68 | 2020-2025 | Arikayce, Brinsupri |
| Inspire Medical Systems, INC. | $396.83 | 2024-2025 | Inspire |
| Merck Sharp & Dohme LLC | $338.07 | 2019-2024 | Zerbaxa, Recarbrio, Keytruda |
| Electromed, INC. | $310.66 | 2021-2025 | Smartvest |
| Mallinckrodt Hospital Products INC. | $300.23 | 2022-2025 | Acthar |
| Inogen, INC. | $267.67 | 2023-2024 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Baxter Healthcare | $239.47 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pulmonx Corporation | $238.21 | 2023-2025 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Genentech USA, INC. | $237.15 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $224.37 | 2022-2025 | Uptravi, Opsumit |
| Verona Pharma, INC. | $185.97 | 2025 | Ohtuvayre |
| Janssen Biotech, INC. | $149.86 | 2025 | Rybrevant, Carvykti |
| Amgen INC. | $141.78 | 2023 | Lumakras, Tezspire |
| Mylan Specialty L.P. | $103.52 | 2021-2024 | Yupelri |
| Philips North America LLC | $88.56 | 2024-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Advanced Respiratory, INC | $74.08 | 2020-2021 | |
| Lilly USA, LLC | $69.94 | 2025 | Zepbound |
| Teva Pharmaceuticals USA, INC. | $68.08 | 2021 | |
| Fisher & Paykel Healthcare INC | $47.09 | 2024-2025 | Fisher & Paykel Healthcare |
| Gilead Sciences, INC. | $41.43 | 2023-2024 | Veklury |
| Sunovion Pharmaceuticals INC. | $23.73 | 2019 | |
| Hikma Pharmaceuticals USA | $16.69 | 2025 | Ryaltris |
| Janssen Pharmaceuticals, INC | $16.54 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepika Aneja listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.